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Abstract
Background: Even with drug-eluting stents, the risk of in-stent restenosis (ISR) remains high. The 
goal of this study was to investigate the use of an endothelial progenitor cell (EPC) capture stent plus 
regional EPC transplantation to reduce the ISR rate. 
Methods: Endothelial progenitor cell capture stents were fabricated using fibrin gel and anti-CD34 
plus anti-VEGFR-2 dual antibodies. Twenty male New Zealand white rabbits established as an ath-
erosclerotic model were randomly divided into two groups: group 1 (n = 10), in which EPC capture 
stents were deployed into the right iliac artery; and group 2 (n = 10), in which sirolimus-eluting stents 
were placed. In both groups, EPCs were transplanted into target vessels beyond the stents, with outflow 
blocked. Radiologic-pathologic correlation outcomes were reviewed after 2 months. 
Results: The technical success rate of EPC capture stent placement plus EPC transplantation was 
100%. The ISR rate in group 1 was lower than in group 2 (1/10 vs. 4/10; p > 0.05). Minimal luminal 
diameters were larger in group 1 than in group 2 (computed tomographic angiography, 1.85 ± 0.15 mm 
vs. 1.50 ± 0.20 mm; duplex ultrasound, 1.90 ± 0.10 mm vs. 1.70 ± 0.30 mm; p > 0.05). Transplanted 
EPCs were tracked positively only in group 1. Pathologic analysis demonstrated neointimal hyperplasia 
thickness of 0.21 ± 0.09 mm in group 1 vs. 0.11 ± 0.07 mm in group 2 (p < 0.05). 
Conclusion: Endothelial progenitor cell capture stent placement plus local EPC transplant decreases 
the ISR rate through thrombosis reduction rather than through neointimal hyperplasia inhibition. 
(Cardiol J 2019; 26, 3: 283–291)
Key words: in-stent restenosis, thrombosis, endothelial progenitor cells, transplantation, 
drug-eluting stent
Introduction
Cardiovascular disease (CVD) remains the 
leading cause of morbidity and mortality in the 
Western world and developing countries. Accord-
ing to the American Heart Association statistics 
committee, CVD is responsible for higher costs 
than any other disease process [1]. 
With advances in quality of care, endovascular 
interventions have improved mortality rates among 
patients with CVD; however, in-stent restenosis 
(ISR) remains the greatest obstacle in coronary in-
terventional treatment. Drug-eluting stents (DES) 
have been shown to dramatically reduce the rates 
of restenosis and target lesion revascularization 
when compared with bare-metal stents (BMS) in 
284 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 3
short- and mid-term studies [2–5]. However, as 
more complex cases have been included in this 
research, it has become apparent that the rate of 
ISR with DES is much higher than initial trials had 
revealed, with rates as high as 20%; long-term 
results are especially dismal [6, 7]. 
In light of this, treatment of DES ISR has be-
come a topic of interest for clinicians. For interven-
tional cardiologists, the greatest dilemma may be 
how to treat a patient with DES ISR in the absence 
of any clear-cut guidelines. The modalities available 
for treatment of DES ISR include routine plain old 
balloon angioplasty, use of cutting or scoring bal-
loons, use of drug-coated balloons or drug-eluting 
balloons, use of BMS, use of same DES or different 
DES, vascular brachytherapy, bypass surgery, use of 
stent-grafts, or laser atherectomy [8–15]. However, 
none of these modalities is optimal.
Treating these patients is difficult in part be-
cause the mechanisms of ISR and delayed ISR with 
DES have not been fully investigated. Some studies 
have suggested that the underlying mechanism of 
ISR is related to incomplete stent endothelializa-
tion [3, 9–11]. If rapid re-endothelialization occurs, 
the lining of the stent provides a nonthrombogenic 
surface, interrupting cytokine-driven activation of 
smooth muscle cells (SMCs) in vascular tissues 
and accelerating normal wound healing; in this way, 
late-stage ISR can be alleviated [16]. Thus, cell 
therapy appears to be an appealing option in these 
patients. Several studies (mostly experimental 
animal studies) have evaluated this rapid re-en-
dothelialization strategy by stent strut recruitment 
of circulation endothelial progenitor cells (EPCs). 
These studies demonstrated the positive role of en-
hanced endothelial regeneration in inhibiting acute 
thrombosis and excessive inflammatory response, 
facilitating the recovery process, and success-
fully minimizing severe pseudointimal hyperplasia 
[17–22]. However, a commercially available EPC 
capture stent (Genous Bio-engineered R stent, 
OrbusNeich Medical, Fort Lauderdale, Florida, 
USA) has not demonstrated the ability to reduce 
neointimal hyperplasia as the designers had ex-
pected. The HEALING trials, which assessed the 
Genous R stent, demonstrated only slight improve-
ments in rapid re-endothelialized intima forma-
tion and the need for short-term dual antiplatelet 
therapy after stent placement; this stent was also 
found to be noninferior to DES with respect to 
target lesion revascularization and rate of major 
adverse cardiac events [23–26].
This study therefore sought to investigate 
the feasibility of using a dual antibody-coated 
EPC capture stent enhanced with regional EPC 
transplantation to reduce the rate of ISR through 
rapid re-endothelialization in an atherosclerotic 
animal model. This study also sought to address 
the controversy regarding whether rapid re-en-
dothelialization inhibits neointimal hyperplasia in 
the setting of ISR.
Methods
This study was carried out in accordance with 
recommendations from the Guide for the Care 
and Use of Laboratory Animals from the National 
Institutes of Health. The Institutional Animal Care 
and Use Committee of Jiangsu University approved 
the study. 
EPC culture
Endothelial progenitor cells were isolated 
from newly drawn male New Zealand white rab-
bit (Jingling Farm Center for Animal Experi-
ments, Nanjing, China) peripheral blood via the 
density gradient centrifuge method. Methods for 
EPC isolation, culture, and characterization have 
been described previously [27]. Briefly, second-
generation EPCs were harvested on day 12. The 
phenotypes of CD34, VEGFR-2, and vWF were 
positively expressed by these cells. The presence 
of up-taken DiI-Ac-LDL and binding FITC-UEA-1 
was confirmed by inverted fluorescence micros-
copy, indicating that these cells were functional 
EPCs (Fig. 1).
In vitro dual antibody-coated  
stent fabrication
Ten nitinol balloon-expandable 3.0 mm × 15 mm 
316L stainless steel open-cell design Sun BMS 
(SINO Medical Sciences Technology Inc, Tian-
jin, China) were immersed in fibronectin solution 
(100 µg/mL; Gene Operation, Ann Arbor, USA) and 
incubated at 37°C in 5% CO2 for 24 h. Coated rab-
bit anti-rabbit CD34 (Bioss, Beijing Biosynthesis 
Biotechnology Co., Ltd, Beijing, China) and anti-
rabbit VEGFR-2 (Bioss) stents were constructed in 
a wet-to-dry lyophilized fashion by bathing the stent 
in the dual-antibody solution (100 µg/mL) for 1 min 
and then using a hair dryer to blow dry the stent for 
1 min, thus increasing antibody adhesion. This pro-
cess was repeated 5 times. The scheduled transplant 
EPCs were labeled with fluorescent cell marker 
(CM-DiI; Invitrogen,Carlsbad, USA) as previously 
described [28]. Dual antibody-coated EPC capture 
stents were then transported from the laboratory to 
the angiography suite in a sterile fashion.
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In vivo stent placement  
and cell transplantation
Twenty male New Zealand white rabbits aged 
2 months and established as atherosclerotic models 
were fed a high-lipid diet (normal diet with added 
2% cholesterol, 5% fat, 7.5% yolk powder) at 
Southeast University Experimental Animal Center 
(Nanjing, China) for at least 1 month before stent 
deployment. The rabbits were injected intrave-
nously with 10% bovine serum album (Biosharp, 
Roche, Shanghai, China) 25 mg/kg once daily for 
3 consecutive days to induce an immune injury 
reaction [29]. Serum hypercholesterolemia was 
demonstrated via laboratory examination. The 
animals (mean weight, 3.1 ± 0.3 kg) were then 
randomly divided into one of two study groups: 
group 1 (n = 10) or group 2 (control group; n = 10). 
On the angiography table, the animals were 
placed under general anesthesia with intravenous 
phenobarbital (Simcare, Beijing, China) 30 mg/kg; 
local anesthesia with 2% lidocaine (China Otsuka 
Pharmaceutical Co., Ltd, Tianjin, China) 4.5 mg/kg 
was administered via subcutaneous infiltration 
before surgical incision. For all animals, patent 
airway and ventilation were maintained throughout 
the procedure, the circulatory systems were also 
supported with the administration of intravenous 
fluids. 
Methods for creation of balloon injury and 
percutaneous stent placement in iliac arteries 
have been described previously [17]. In this study, 
a 4-French introducer sheath (Radifocus, Terumo, 
Japan) was surgically introduced into the right ca-
rotid artery and a 2.7 Fr microcatheter (Progreat, 
Terumo, Japan) was sub-selectively advanced into 
the lower abdominal aorta under fluoroscopic guid-
ance (Zeego, Siemens, Forchheim, Germany). Post 
systemically heparinized with 200 IU/kg heparin 
sodium (Shanghai No.1 Biochemical Pharmacology 
Co. Ltd,Shanghai, China), maneuvers to create 
a balloon injury were performed 3 times with 
a 2.5 mm × 15 mm balloon catheter (Star Progress 
Medical Ltd., Shanghai, China) at 6 atmospheres 
of pressure for 30 s in the right common external 
iliac artery. After the balloon injury was created, 
ten 3.0 mm × 15 mm dual antibody-coated Sun 
BMS (group 1) or ten 3.0 mm × 14 mm sirolimus-
eluting stents (Excel, JW Medical System, Weihai, 
China) (group 2) were randomly deployed at the 
dilated site of the right iliac arteries. Simultane-
ously, a mean amount of 5 × 106 EPCs labeled 
with DiI were continuously infused through the 
microcatheter just above the proximal edge of the 
stent, with a tourniquet placed on the ipsilateral 
thigh to block blood runoff for 2 min. After stent 
deployment, angiography was performed in all 
animals to exclude any acute thrombus formation. 
Postprocedural follow-up
Penicillin 800,000 IU was administered intra-
muscularly daily for 3 days after the procedure. The 
animals were fed the high-lipid diet, provided with 
water ad libitum, and given oral acetylsalicylic acid 
12.5 mg once daily during follow-up. One month 
after the procedure, with the animals under general 
anesthesia, computed tomography angiography 
(CTA) was performed using 2.5 mL/kg nonionic 
iodine medium (Omnipaque, Yangzi Pharmacy 
Ltd., Taizhou, China) via power injection through 
an ear edge vein; a dual-source CT SOMATOM 
Figure 1. Inverted fluorescent microscopy images of endothelial progenitor cells (EPCs) that endocytosed DiI-Ac-LDL (A) 
and bound FITC-UEA-1 (B). The EPCs (overlay of A and B) are stained yellow (C). Scale bar = 50 μm.
A B C
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Definition Flash scanner (Siemens AG, Forchheim, 
Germany) was used for all scans (140 KV and 80 KV; 
automatically controlled mAs; 10-s delay). CTA 
data were analyzed using vascular analysis soft-
ware (Syngo.via, Siemens AG). After CTA was 
completed, a color Doppler duplex ultrasound 
examination (Philips HD7 XE, Amsterdam, the 
Netherlands) was performed to investigate target 
vessel preparation with the affected limb shaved. 
CTA and duplex ultrasound examinations were 
repeated 2 months thereafter before the animals 
were euthanized. The patency of the target vessel, 
minimum luminal diameter, and velocity of blood 
were recorded during these examinations. 
Restenosis definition
Binary restenosis is defined as 50% luminal 
narrowing on follow-up angiography [3]. For this 
study, ISR was determined by visual estimation and 
was defined as > 50% luminal narrowing within 
5 mm proximal or distal to the stent. According to 
the current clinical literature, restenosis is identi-
fied as “very late” when it occurs 1 year after stent 
placement in humans [11]. For this animal study, 
the authors defined ISR as restenosis occurring 
2 months after stent placement to account for the 
differences between rabbits and humans in life 
expectancies.
Pathologic assessment
The animals were euthanized with 5 mL intra-
venous 10% KCl administered after 2 months of 
follow-up. Necropsy was performed immediately. 
The iliac artery with the stent was evaluated with 
gross photography and preserved for histologic 
assessment. Snap frozen slides were prepared in 
Optimum Cutting Temperature compound (Sakura 
Finetek Inc., Torrance, California, USA) to test 
the artery at the proximal and distal ends of the 
stent for DiI fluorescent stained cells. After tis-
sue fixation in buffered 4% formaldehyde (Guduo 
Biotechnology, Shanghai, China) for 24 h, the re-
maining tissue with stent in place was embedded 
in methyl methacrylate (Hubei Jusheng Bioscience, 
Wuhan, China) for hard tissue slicing. Tissue seg-
ments of proximal, central, and distal regions of the 
stent were then cut into 6-micron sections with 
a diamond blade, and these segments were stained 
with hematoxylin-eosin. Immunohistochemistry 
staining was performed on separate sections 
using standard techniques to identify CD34 and 
VEGFR-2 phenotype expression.
The pseudointimal thickness from the stent 
struts to the lumen surface was measured at 
6 equidistant points around the graft circumference 
(excluding the thrombus). The pseudointimal area 
and minimum luminal diameter were measured 
with microscopy using a LEICA DM LB2 micro-
scope (Leica Microsystems Wetzlar GmbH, Wet-
zlar, Germany), and the morphometry was analyzed 
with software (LEICA Qwin v3).
Statistical analysis
Statistical analysis was performed using SPSS 
Version 19.0 (SPSS, Inc., Chicago, Illinois, USA). 
Continuous variables were expressed as mean 
± standard deviation (SD). An unpaired Student 
t test was used to compare the EPC capture and 
DES groups. Categorical data were compared 
with a c2 test or with the Fisher exact test when 
the expected cell value was < 5. A p value ≤ 0.05 
(2-sided) was considered statistically significant.
Results
Stent placement and  
EPC local transplantation
The technical success rates of stent place-
ment and EPC transplantation were 100% for both 
groups. Anesthesia accident and cardiac arrest 
cases (n = 2) that occurred during the preliminary 
study were excluded from review. No cases of 
acute thrombosis, stent malposition, or infection 
occurred during the procedures. 
Follow-up data: laboratory and imaging
After consuming a high-lipid diet for 1 month 
before stent placement, the rabbits had a mean 
serum cholesterol level of 37.9 ± 1.1 mmol/L, 
triglyceride level of 3.4 ± 2.3 mmol/L, and low-
density lipoprotein cholesterol level of 26.1 ± 2.3 
mmol/L, nearly 2- to 8-fold higher than the upper 
limits of normal values. Fatty liver, arterial athero-
sclerotic plaque, and foam cells were detected on 
microscopy examination. 
One month after stent placement, CTA dem-
onstrated that all stents were patent in group 1; 
color Doppler sonography demonstrated 1 case 
of distal end ISR in group 1, although this case 
appeared normal on CTA. In Group 2, 1 case of 
proximal restenosis and 1 case of total occlu-
sion were detected by both CTA and ultrasound, 
8 stents were patent. Two months after stent place-
ment, CTA demonstrated that 9 stents were patent 
in group 1, with 1 distal end ISR; in group 2, there 
were 3 cases of ISR and 1 case of occlusion (Fig. 2), 
6 stents were patent. Therefore, the ISR rate was 
1/10 in group 1 and 4/10 in group 2 (p = 0.18). 
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Although the in-stent minimal diameter and 
luminal area in group 2 trended somewhat smaller 
than the in-stent minimal diameter and luminal area 
in group 1, these differences were not statistically 
significant (p > 0.05; Table 1). 
As measured by duplex ultrasound, the veloc-
ity of blood in the stent was 61.2 ± 14.4 cm/s in 
group 1 vs. 74.4 ± 9.0 cm/s in group 2 (p > 0.05), 
and the minimal diameter of the stent was 1.90 ± 
± 0.10 mm in group 1 vs. 1.70 ± 0.30 mm in 
group 2 (p > 0.05). 
Pathologic analysis of stent segments
DiI-positive cells were extensively detected 
in samples of the luminal side of the artery from 
group 1, indicating that the transplanted EPCs 
Figure 2. Multiplanar reformatted computed tomography angiography images of endothelial progenitor cells (EPCs) 
capture stent in group 1 (A) and drug-eluting stent in group 2 (B) after 2 months of follow-up. Microscopy of hema-
toxylin-eosin staining in group 1 (C, E) and group 2 (D, F) in hard tissue slices. Neointimal hyperplasia was markedly 
thicker in group 1 than in group 2, and a red thrombus was revealed in the stent lumen in group 2. Immunohistochemi-
cal microscopy revealed CD 34+ staining cells (brown) closely lining the endothelium in group 1 (G) but loosely lining 
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Table 2. Morphometry analysis of samples from group 1 and group 2.
Group Minimum luminal  
diameter [mm]
Neo-intimal hyperplasia  
thickness [mm]*
Intimal hyperplasia  
area [mm2]*
1 2.28 ± 0.38 0.21 ± 0.09 1.82 ± 0.52
2 2.68 ± 0.12 0.11 ± 0.07 0.92 ± 0.52
*p < 0.05. Group 1 — anti-CD34, anti-VEGFR2 dual antibody coated endothelial progenitor cell capture stent group, Group 2 — sirolimus-
-eluting stent group
Table 1. Computed tomography angiography data of different site stent luminal diameter and area.
Group Luminal diameter [cm] Luminal area [cm2]
Proximal Minimal Distal Proximal Minimal* Distal
1 2.38 ± 0.39 1.85 ± 0.15 2.30 ± 0.50 5.10 ± 1.43 3.05 ± 0.45 4.83 ± 1.97
2 2.43 ± 0.49 1.50 ± 0.20 2.23 ± 0.78 5.50 ± 2.13 1.97 ± 0.44 4.80 ± 3.20
*p < 0.05. Group 1 — anti-CD34, anti-VEGFR2 dual antibody coated endothelial progenitor cell capture stent group, Group 2 — sirolimus-
-eluting stent group
grew and differentiated to endothelial cells among 
the pseudointima layer. DiI-positive cells were 
observed sporadically in samples from group 2.
Microscopy demonstrated integrity of the 
endothelium layer and exuberant neointimal hy-
perplasia in group 1. CD34 and VEGFR-2 were 
positively expressed on the luminal side in group 1. 
In group 2, almost no intact monolayer endothelium 
formation was observed, but 3 red thrombi were 
detected in the stent lumen (Fig. 2). Morphometry 
demonstrated that the thickness of the neointima 
in group 1 was significantly greater than in group 2 
(0.21 ± 0.09 mm vs. 0.11 ± 0.07 mm; p < 0.05). 
The neointimal area was significantly larger in 
group 1 (1.82 ± 0.52 mm2 vs. 0.92 ± 0.52 mm2, 
p < 0.05), and the minimum luminal diameter 
was significantly smaller in group 1 (excluding 
thrombus, 2.28 ± 0.38 mm vs. 2.68 ± 0.12 mm, 
p < 0.05) (Table 2). 
Discussion
In this study, transplanted EPCs could be de-
tected on the stent luminal side and were found to 
have differentiated to functional endothelial cells in 
vivo in the EPC capture stent group. These results 
suggest that it is feasible to use a dual antibody-
coated EPC capture stent combined with local EPC 
delivery to achieve rapid re-endothelialization in 
vivo. A nonsignificant trend toward a reduced rate 
of late-stage ISR (achieved via inhibition of in-stent 
thrombosis rather than via reduction of neointimal 
hyperplasia) in the EPC capture stent group was 
also noted. 
These results differ from those seen in some 
previous animal studies [17–19]. The authors of 
these studies concluded that recruiting circula-
tion EPCs on the stent may promote re-endothe-
lialization and inhibit neointimal hyperplasia via 
the same process. They suggest that the integral 
endothelium seems not only to prevent neointimal 
hyperplasia but also to prompt the normal healing 
process and decrease the rate of acute and chronic 
thrombosis. Conversely, clinical studies with the 
Genous R stent and the current study failed to dem-
onstrate this inhibition of neointimal hyperplasia. 
One possible explanation for this difference is that 
recruited circulation CD34 EPCs may also transdif-
ferentiate to SMCs under certain conditions (e.g., 
in the presence of transforming growth factor-beta) 
[30], suggesting that the specific microenviron-
ment for EPCs determines their fate and the ef-
fects of cellular therapy. Therefore, more efforts 
are needed to improve the EPC microenvironment, 
which can enhance therapeutic potential [31]. 
Injury of the endothelium is the first step in 
atherosclerosis and is the predisposing factor for 
the occurrence of ISR. Recent studies have sug-
gested that EPCs can treat regional ischemia or 
injured vessels by prompting angiogenesis [31, 
32]. These EPCs, which can be easily harvested 
from peripheral blood, bone marrow, or the um-
bilical vein, differentiate into mature endothelial 
cells in vivo. Previous work demonstrated that 
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EPCs can be successfully seeded on BMS struts in 
vitro and in vivo, and this EPC seeding was found 
to improve patency in transjugular intrahepatic 
portosystemic shunts in a porcine model [33, 34]. 
According to available research, in patients with 
severe atherosclerosis, diabetes, history of heavy 
smoking, hypercholesterolemia, or older age, there 
is an extreme paucity of EPCs available in the 
circulation, and the function of the EPCs that are 
present is compromised to a certain extent. Local 
transplantation of allogenous EPCs is a potential 
option to address this issue [35]. In this study, two 
different modalities of cell therapy (implanting 
EPCs and using specific antibody-coated stent-
based therapy) were included in an attempt to re-
cruit EPCs. The number of DiI-positive cells from 
the intima layer was markedly higher in the EPC 
capture stent group than in the DES group. These 
results suggest that locally transplanted EPCs are 
effectively captured by dual antibody-coated stent 
struts, homing to the wounded site and incorporat-
ing into the intima components.
Drug-eluting stent inhibit not only SMC prolif-
eration but also endothelial cell growth, which may 
explain why no intact endothelium was detected in 
the DES group in this study. The higher total ISR 
rate in the DES group was likely due to delayed 
re-endothelialization, inadequate antibiotic prophy-
laxis, and invasive surgical protocol [2, 16, 29].
Restenotic and thrombotic processes may oc-
casionally coexist, especially in cases characterized 
by neointimal hyperplasia plus focal thrombosis 
inside the stent [3, 36, 37]. The “thromboreste-
nosis” phenomenon is a theory describing how 
chronic thrombus formation may play an integral 
role in the development of ISR [38]. Recently, 
Alfonso et al. suggested that the substrate of ISR 
encompasses a pathologic spectrum ranging from 
SMC proliferation to neoatherosclerosis [39, 40]. 
Among currently available therapeutic modalities 
for these patients, DES and drug-eluting balloons 
provide the best clinical and angiographic results in 
patients with ISR. The investigators suggested that 
everolimus-eluting stents should be considered 
the first-line therapy of choice in these challenging 
scenarios. However, to prevent a primary episode 
of ISR, combining EPC-capturing technology with 
drug-eluting technology may be a promising ap-
proach for improving clinical outcomes in the future 
[31]. Further studies are needed to explore this 
potential approach. Further studies are also needed 
to determine whether a dual antibody-coated EPC 
capture stent has a synergistic effect or whether it 
is more effective than a single antibody- or gene-
coated stent. 
Limitations of the study
This study had several limitations. First, be-
cause the stent was placed in a peripheral rather 
than a coronary conduit, the rate and mechanism 
of ISR may not have been identical across cases. 
Second, the small sample size limited the statistical 
power of the study. Third, using only male animals 
may have resulted in sex selection bias, potentially 
influencing outcomes. Fourth, premature discon-
tinuation of dual antiplatelet therapy (without the 
use of clopidogrel and cilostazol) varies across clini-
cal settings, which may affect the interpretation of 
these results. Finally, previous studies have shown 
that DES is superior to BMS in preventing in-stent 
stenosis in most clinical settings, and EPC-coated 
stents have been demonstrated to be more effec-
tive than BMS in inhibiting neointima hyperplasia 
[17–19, 41, 42]. Therefore in this experimental 
study, the authors directly compared the modified 
EPC-capture stent with DES; further studies in-
corporating a larger sample size and with a more 
robust design (such as including a BMS control 
arm) are needed.
Conclusions
Use of a dual antibody-coated EPC capture 
stent concomitant with local EPC transplant de-
creased the rate of ISR in vivo when compared 
with DES in an atherosclerotic animal model. This 
reduced ISR with the use of EPC capture stents 
may be achieved through a reduction in the in-stent 
thrombosis rate rather than through inhibition of 
neointimal hyperplasia. 
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